Health and Fitness Health and Fitness
Wed, December 8, 2010
[ Wed, Dec 08th 2010 ] - Market Wire
Medisafe 1 Technologies Meets With Israel's Minis .. r of Health to Demonstrate Syringe Locking Device
[ Wed, Dec 08th 2010 ] - Market Wire
Geron Corporation Announces Full Exercise of Over-Allotment Option
[ Wed, Dec 08th 2010 ] - Market Wire
Faruqi & Faruqi, LLP Is Investigating Genoptix, Inc. On Behalf of Its Shareholders - GXDX
[ Wed, Dec 08th 2010 ] - Market Wire
Faruqi & Faruqi, LLP Announces Investigation Rela .. saction of Caraco Pharmaceutical Laboratories Ltd
[ Wed, Dec 08th 2010 ] - Market Wire
XenoPort Announces Proposed Public Offering of Common Stock
[ Wed, Dec 08th 2010 ] - Market Wire
Alnylam to Webcast Presentation at 2010 Deutsche Bank BioFEST
[ Wed, Dec 08th 2010 ] - Market Wire
El programa Give for Real de Mannatech permite qu .. na importante donacin a la Fundacin Vamos M©xico
[ Wed, Dec 08th 2010 ] - Market Wire
Alkermes Announces Results from Phase 2 Study of ALKS 33 in Alcohol Dependence
[ Wed, Dec 08th 2010 ] - Market Wire
St. Jude Medical Advances Integration of Electrop .. Equipment with Launch of Several New Technologies
[ Wed, Dec 08th 2010 ] - Market Wire
ImmunoCellular Therapeuticsa? Chief Executive Off .. resent at Prestigious Cancer Stem Cell Conference
[ Wed, Dec 08th 2010 ] - Market Wire
CHINA HEALTH LABS &; DIAGNOSTICS LTD. ANNOUNCES R .. CH &; DEVELOPMENT AGREEMENT WITH CHINESE MILITARY
[ Wed, Dec 08th 2010 ] - Market Wire
CIGNA Announces Completion of Tender Offer for Any and All of Its 8.50% Senior Notes Due 2019
[ Wed, Dec 08th 2010 ] - Market Wire
InSite Vision to Host Investor Conference Call Introducing New CEO Timothy Ruane
[ Wed, Dec 08th 2010 ] - Market Wire
CytRx Announces Compliance with NASDAQ's Minimum Bid Requirement
[ Wed, Dec 08th 2010 ] - Market Wire
Clinical Data, Inc. Announces Vilazodone Data Pre .. at American Society of Health System Pharmacists
[ Wed, Dec 08th 2010 ] - Market Wire
Cubist Pharmaceuticals to Present at December Investor Conference
[ Wed, Dec 08th 2010 ] - Market Wire
Beobachtungsstudie zeigt kein hheres Auftreten de .. atischen Leukmie mit REVLIMID® bei Patienten mit
[ Wed, Dec 08th 2010 ] - Market Wire
Une ©tude observationnelle ne d©montre aucune i .. s la leuc©mie my©lode aigu avec REVLIMID® chez
[ Wed, Dec 08th 2010 ] - Market Wire
Emergent BioSolutions to Webcast Presentation at JPMorgan Healthcare Conference
Tue, December 7, 2010
[ Tue, Dec 07th 2010 ] - Market Wire
CIGNA Announces Pricing of Tender Offer for Any and All of Its 8.50% Senior Notes Due 2019
[ Tue, Dec 07th 2010 ] - Market Wire
The Law Office of Abe Shainberg Launches an Inves .. eaches of Fiduciary Duty by the Board of Caraco P
[ Tue, Dec 07th 2010 ] - Market Wire
Daten aus drei Studien, die den klinischen Nutzen .. deltem multiplen Myelom beurteilen, werden auf de
[ Tue, Dec 07th 2010 ] - Market Wire
Un'analisi retrospettiva dei dati clinici derivat .. REVLIMID® (MDS-004) riporta un miglioramento si
[ Tue, Dec 07th 2010 ] - Market Wire
Clinical Data from Two Phase II Studies Evaluatin .. Indolent Non-Hodgkina?s Lymphomas Presented at A
[ Tue, Dec 07th 2010 ] - Market Wire
Retrospective Analysis of Clinical Data from REVL .. 04) Reports a Significant Improvement in Survival
[ Tue, Dec 07th 2010 ] - Market Wire
Seattle Genetics and Millennium Report Positive D .. entuximab Vedotin (SGN-35) in Relapsed or Refract
[ Tue, Dec 07th 2010 ] - Market Wire
Pro-Pharmaceuticals Expands Patent Coverage to Australia
[ Tue, Dec 07th 2010 ] - Market Wire
Les donn©es de trois pr©sentations ©valuant le .. mide chez les patients atteints de my©lome multi
[ Tue, Dec 07th 2010 ] - Market Wire
Orthovita Receives FDA Clearance for Vitossa" Bioactive Foam-2X Bone Graft Substitute
[ Tue, Dec 07th 2010 ] - Market Wire
Affymax to Present at the Deutsche Bank 2010 BioFEST Conference

Affymax to Present at the Deutsche Bank 2010 BioFEST Conference


Published on 2010-12-07 16:00:52 - Market Wire
  Print publication without navigation


PALO ALTO, Calif.--([ BUSINESS WIRE ])--Affymax, Inc. (Nasdaq: AFFY) today announced that Arlene Morris, the company's chief executive officer, will present at Deutsche Bank's 2010 BioFEST Conference on Tuesday, December 14, 2010, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time) at the Four Seasons Hotel in Boston.

A live webcast of the presentation will be available on the investors section of the Company's website at [ www.affymax.com ]. A replay will also be available for 30 days following the presentation.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. For additional information, please visit [ www.affymax.com ].

Contributing Sources